2023 World Conference on Lung Cancer (Posters)-EP08.02. Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience

EP08.02. Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the outcomes of patients with unresectable stage IIB-III non-small cell lung cancer (NSCLC) who were not eligible for the standard treatment of concurrent chemotherapy and radiation followed by durvalumab. Instead, these patients received definitive hypofractionated radiation therapy with or without sequential chemo/immunotherapy. The study included 41 patients who were not eligible for standard treatment due to poor performance status or ineligibility for systemic therapy. The median age of the patients was 73.<br /><br />The results showed that the median overall survival (OS) was 9 months and the median progression-free survival (PFS) was 6 months for the entire cohort. Among patients who received sequential immunotherapy after radiation therapy, the median PFS was 10 months, compared to 6 months for those who did not receive immunotherapy. However, this difference was not statistically significant.<br /><br />The study also reported treatment-related toxicities, with 32% of patients experiencing no toxicities, 54% experiencing grade 1 adverse effects, and 19% experiencing grade 2 adverse effects. No patients experienced grade 3 or higher adverse effects.<br /><br />Overall, the study suggests that definitive hypofractionated radiation therapy can be a safe and effective treatment option for unresectable NSCLC patients who are not eligible for the standard treatment regimen. The use of sequential immunotherapy in this patient population appears to be well tolerated and may warrant further investigation. This study adds to the limited reported experiences in managing unresectable NSCLC patients who are not eligible for standard treatment.

Asset Subtitle

Benjamin Hopkins

Meta Tag

Speaker Benjamin Hopkins

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

unresectable stage IIB-III non-small cell lung cancer

standard treatment

concurrent chemotherapy

radiation

definitive hypofractionated radiation therapy

sequential chemo/immunotherapy

overall survival

progression-free survival

treatment-related toxicities

unresectable NSCLC